Michael F.  Marino, III net worth and biography

Michael Marino, III Biography and Net Worth

Insider of OptiNose
Michael Marino joined Optinose in January 2017 as Chief Legal Officer. In this role, Mr. Marino serves as Corporate Secretary to the Board of Directors and has overall responsibility for leading the legal function including legal and intellectual property strategy, risk management, compliance, contracting and advising the Company on strategic transactions, financings and corporate governance matters.

Mr. Marino is a seasoned executive and legal advisor with more than 15 years of experience advising public and privately held companies in a diverse range of industries – most notably life sciences. Prior to joining Optinose, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of Fibrocell, a publicly held cell and gene therapy company. Prior to Fibrocell, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of NuPathe, a publicly held specialty healthcare company, from 2010 until its acquisition by Teva Pharmaceuticals in 2014. During his tenures at Fibrocell and NuPathe, Mr. Marino secured the issuance of numerous US and foreign patents, successfully managed litigation matters, implemented and enhanced compliance programs and led the legal negotiations for public and private financing transactions, licensing and collaboration arrangements and the sale of NuPathe.

Before joining NuPathe, Mr. Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP in Philadelphia, PA, and WilmerHale LLP in Boston, MA, where his practice focused on mergers and acquisitions, collaborations, financing transactions, corporate governance, securities and other general corporate matters.

Mr. Marino holds a JD from Boston College Law School and a Bachelor of Science in accountancy from Villanova University.

What is Michael F. Marino, III's net worth?

The estimated net worth of Michael F. Marino, III is at least $264,222.72 as of July 17th, 2024. Mr. Marino, III owns 550,464 shares of OptiNose stock worth more than $264,223 as of November 24th. This net worth approximation does not reflect any other investments that Mr. Marino, III may own. Learn More about Michael F. Marino, III's net worth.

How do I contact Michael F. Marino, III?

The corporate mailing address for Mr. Marino, III and other OptiNose executives is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. OptiNose can also be reached via phone at (267) 364-3500 and via email at [email protected]. Learn More on Michael F. Marino, III's contact information.

Has Michael F. Marino, III been buying or selling shares of OptiNose?

Michael F. Marino, III has not been actively trading shares of OptiNose over the course of the past ninety days. Learn More on Michael F. Marino, III's trading history.

Who are OptiNose's active insiders?

OptiNose's insider roster includes Victor Clavelli (Insider), Keith Goldan (CFO), Ramy Mahmoud (COO), Michael Marino, III (Insider), and Peter Miller (CEO). Learn More on OptiNose's active insiders.

Are insiders buying or selling shares of OptiNose?

In the last year, insiders at the sold shares 11 times. They sold a total of 295,529 shares worth more than $374,251.18. The most recent insider tranaction occured on July, 17th when CAO Anthony J Krick sold 6,845 shares worth more than $7,803.30. Insiders at OptiNose own 2.7% of the company. Learn More about insider trades at OptiNose.

Information on this page was last updated on 7/17/2024.

Michael F. Marino, III Insider Trading History at OptiNose

See Full Table

Michael F. Marino, III Buying and Selling Activity at OptiNose

This chart shows Michael F. Marino III's buying and selling at OptiNose by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OptiNose Company Overview

OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $0.48
Low: $0.39
High: $0.48

50 Day Range

MA: $0.68
Low: $0.34
High: $0.89

2 Week Range

Now: $0.48
Low: $0.32
High: $2.10

Volume

1,285,623 shs

Average Volume

1,144,020 shs

Market Capitalization

$72.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A